CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 28 enrolled
Drug / intervention
vismodegib (150 mg PO daily)drug
Likely dose
vismodegib (150 mg PO daily)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01700049
NCT01700049Phase 2Completed
CompareCT.gov

ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform,Nodular and Superficial)of High Risk and/or Locally Advanced Basal Cell Carcinoma

Mayo Clinic·interventional·Posted Oct 4, 2012·Updated May 23, 2019

In Brief

A Phase 2 clinical trial evaluating vismodegib (150 mg PO daily) for Basal Cell Carcinoma. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBasal Cell Carcinoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 4, 2012
Enrollment StartJan 14, 2013
Primary CompletionJul 3, 2017
Study CompletionJul 3, 2018
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 13.7 years ago

Interventions

vismodegib (150 mg PO daily)drug

Biopsies will be performed on all participants at baseline, week 12 and week 24.